COVID-19 and diabetic ketoacidosis: case reports and review

Česká verzia

Authors: Mária Kachlíková; Peter Sabaka
Authors place of work: Klinika infektológie a geografickej medicíny LF UK, SZU a UNB, Nemocnica akad. L. Dérera, Bratislava
Published in the journal: Forum Diab 2022; 11(1): 52-55
Category: Case Reports

Summary

Diabetes mellitus is one of the most important risk factor of severe course of coronavirus disease 2019 (COVID-19). On the other hand, COVID-19 often leads to metabolic decompensation and even to a developement of diabetic ketoacidosis in patients with not just type 1 but also type 2 diabates mellitus. Development of diabetic ketoacidosis in the setting of severe COVID-19 impairs a prognosis and complicates treatment. We present 2 cases of diabetic ketoacidosis in patients with severe COVID-19, in which ketoacidosis and metabolic decompensation of diabetes significantly impaired the course of their disease. It also reviews the current evidence linking COVID-19 to the development of diabetic ketoacidosis.

Keywords:

diabetes mellitus – COVID-19 – diabetic ketoacidosis

Zdroje

1. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497–506. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(20)30183–5>.
2. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY) 2020; 12(7): 6049–6057. Dostupné z DOI: <http://dx.doi.org/10.18632/aging.103000>.
3. Wu J, Zhang J, Sun X et al. Influence of diabetes mellitus on the severity and fatality of SARS‐CoV‐2 (COVID‐19) infection. Diabetes Obes Metab 2020; 22(10): 1907–1914. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.14105>.
4. Cuschieri S, Grech S. COVID-19 and diabetes: The why, the what and the how. J Diabetes Complications 2020; 34(9): 107637. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jdiacomp.2020.107637>.
5. Li J, Wang X, Chen J, Zuo X et al. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab 2020; 22(10): 1935–1941. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.14057>.
6. Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine (Baltimore) 2014; 42(12): 698–702. Dostupné z DOI: <http://dx.doi.org/10.1016/J.MPMED.2014.09.007>.
7. 2nd Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes – 2021. Diabetes Care 2021; 44(Suppl 1): S15-S33. Dostupné z DOI: <http://dx.doi.org/10.2337/dc21-S002>.
8. Saeedi P, Petersohn I, Salpea P et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th ed. Diabetes Res Clin Pract 2019; 157: 107843. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2019.107843>.
9. Harding JL, Pavkov ME, Magliano DJ et al. Global trends in diabetes complications: a review of current evidence. Diabetologia 2019; 62(1): 3–16. <http://dx.doi.org/10.1007/s00125–018–4711–2>.
10. Poston JT, Patel BK, Davis AM. Management of Critically Ill Adults With COVID-19. JAMA. JAMA 2020; 323(18): 1839–1841. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2020.4914A.
11. Jaeckel E, Manns M, Herrath M. Viruses and Diabetes. Ann N Y Acad Sci 2006; 958(1): 7–25. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1749–6632.2002.tb02943.x>.
12. Yang J-K, Lin S-S, Ji X-J et al. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010; 47(3): 193–199. Dostupné z DOI: <http://dx.doi.org/10.1007/s00592–009–0109–4>.
13. Guo W, Li M, Dong Y et al. Diabetes is a risk factor for the progression and prognosis of COVID-19 Diabetes Metab Res Rev 2020; 36(7): e3319. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.3319>.
14. Zhou J, Tan J. Letter to the Editor. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China. Metabolism 2020; 107: 154216. Dostupné z DOI: <http://dx.doi.org/10.1016/j.metabol.2020.154216>.
15. Fignani D, Licata G, Brusco N et al. SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic β-Cells and in the Human Pancreas Microvasculature. Front Endocrinol (Lausanne) 2020; 11: 596898. Dostupné z DOI: <http://dx.doi.org/10.3389/fendo.2020.596898>.
16. Zhang Y, Li H, Zhang J et al. The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single‐centre, retrospective, observational study in Wuhan. Diabetes Obes Metab 2020; 22(8): 1443–1454. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.14086>.
17. Wang F, Wang H, Fan J et al. Pancreatic Injury Patterns in Patients With Coronavirus Disease 19 Pneumonia. Gastroenterology 2020; 159(1): 367–370. Dostupné z DOI: <http://dx.doi.org/10.1053/j.
gastro.2020.03.055>.18. Liu F, Long X, Zhang B et al. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol 2020; 18(9): 2128–2130.e2. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2020.04.040>.
19. Steenkamp DW, Alexanian SM, McDonnell ME. Adult Hyperglycemic Crisis: A Review and Perspective. Curr Diab Rep 2013; 13(1): 130–137. Dostupné z DOI: <http://dx.doi.org/10.1007/s11892–012–0342-z>.
20. Benoit SR, Zhang Y, Geiss LS et al. Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality – United States, 2000–2014. MMWR Morb Mortal Wkly Rep 2018; 67(12): 362–365. Dostupné z DOI: <http://dx.doi.org/10.15585/mmwr.mm6712a3>.
21. Vitale RJ, Valtis YK, McDonnell ME et al. Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors. AACE Clin Case Reports 2021; 7(1): 10–13. Dostupné z DOI: <http://dx.doi.org/10.1016/j.aace.2020.11.019>.
22. Lim S, Bae JH, Kwon H-S et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 2021; 17(1): 11–30. Dostupné z DOI: <http://dx.doi.org/10.1038/s41574–020–00435–4>.
23. Sathish T, Tapp RJ, Cooper ME et al. Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes. Diabetes Metab 2021; 47(2): 101204. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabet.2020.10.002>.
24. Chamorro-Pareja N, Parthasarathy S, Annam J et al. Letter to the editor: Unexpected high mortality in COVID-19 and diabetic ketoacidosis. Metabolism 2020; 110: 154301. Dostupné z DOI: <http://dx.doi.org/10.1016/j.metabol.2020.154301>.
25. Pasquel FJ, Tsegka K, Wang H et al. Clinical Outcomes in Patients With Isolated or Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State: A Retrospective, Hospital-Based Cohort Study. Diabetes Care 2020; 43(2): 349–357. Dostupné z DOI: <http://dx.doi.org/10.2337/dc19–1168>.
26. de Sá-Ferreira CO, da Costa CHM, Guimarães JCW et al. Diabetic ketoacidosis and COVID-19: what have we learned so far? Am J Physiol Metab 2022; 322(1): E44-E53. Dostupné z DOI: <http://dx.doi.org/10.1152/ajpendo.00244.2021>.